Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zorubicin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Zorubicin is a benzoylhydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin. It exerts its anticancer effects by intercalating into DNA, interacting with and inhibiting topoisomerase II, and inhibiting DNA polymerases. These actions collectively disrupt DNA replication, repair, and the synthesis of RNA and proteins, leading to cell death in various cancer types.
- Brand names
- RubidazonRubidazoneZorubicine
- Other names
- benzoyl hydrazone daunorubicindaunorubicin benzoylhydrazone hydrochloride
02
Targets
DNARNAP (Bacterial dna-dependent RNA polymerase)TOP2A (DNA topoisomerase II)DNA polymerase family
Beyond the preview
Go deeper on Zorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zorubicin.